{
  "id": 16204645,
  "title": "Real-world results confirm benefit of antigen therapy for prostate cancer",
  "url": "https://urgent.news/2026/10/23/real-world-results-confirm-benefit-of-antigen-therapy-for-prostate",
  "topic": "health",
  "section": "Health & Medicine",
  "published": "2026-10-23T17:20:06.000Z",
  "source": {
    "name": "Medical Xpress",
    "slug": "medical-xpress",
    "url": "https://medicalxpress.com/news/2026-10-real-world-results-benefit-antigen.html"
  },
  "original_language": "en",
  "account": null,
  "summary": "Prostate-specific membrane antigen (PSMA)-targeted radiopharmaceutical therapy is safe and effective for patients with metastatic castration-resistant prostate cancer (mCRPC) in routine clinical practice, consistent with outcomes from the VISION trial. An analysis of outcomes from a French early-access program, the largest real-world cohort of patients studied to date, confirms the benefit-risk…",
  "key_points": [],
  "editors_take": null,
  "illustration": null,
  "coverage": {
    "outlets": 1,
    "also_reported_by": []
  },
  "ai_generated": true,
  "disclaimer": "Summaries, key points and the editor’s take are written by software from other outlets’ reporting and may contain errors — always check the linked original."
}